Diamond Biofund (TPE:6901) 3-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6901 Diamond Biofund Inc TPE:6901
24 GF Score
Price NT$16.70
! 2 Warning Signs
View Full Analysis

What is Diamond Biofund 3-Year EBITDA Growth Rate?

Diamond Biofund TPE:6901 +2.14% 24 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates TPE:6901 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 511 Asset Management companies, Diamond Biofund ranks worse than 195694.52% on this metric.

Diamond Biofund's EBITDA per Share for the three months ended in Jun. 2026 was NT$3.97.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Diamond Biofund  (TPE:6901) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Diamond Biofund 3-Year EBITDA Growth Rate Related Terms

TPE:6901 vs BLK, BX, KKR: 3-Year EBITDA Growth Rate Comparison

For the Asset Management subindustry, Diamond Biofund's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamond Biofund 3-Year EBITDA Growth Rate vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Diamond Biofund's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Diamond Biofund's 3-Year EBITDA Growth Rate falls into.


TPE:6901
24GF Score
Diamond Biofund Inc TPE:6901
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biofund 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Diamond Biofund (TPE:6901) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Diamond Biofund and its competitors. According to the industry distribution chart, Diamond Biofund ranks #999999 out of 511 companies in the Asset Management industry.
Is Diamond Biofund's 3-Year EBITDA Growth Rate too high?
Diamond Biofund's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Diamond Biofund ranks #999999 out of 511 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, Diamond Biofund has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's 3-Year EBITDA Growth Rate compare to BLK and BX?
According to the Asset Management industry distribution chart, Diamond Biofund ranks #999999 out of 511 companies for 3-Year EBITDA Growth Rate. This places Diamond Biofund in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for an Asset Management company?
The median 3-Year EBITDA Growth Rate among Asset Management companies is 11.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Diamond Biofund and its competitors. For the Asset Management industry, the median 3-Year EBITDA Growth Rate is 11.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamond Biofund's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Diamond Biofund's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diamond Biofund Business Description

Address Zhongxiao West Road, 34th Floor, No. 66, Section 1, Zhongzheng District, Taipei, TWN, 100
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
24GF Score

Get the complete analysis for TPE:6901

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.70
Price